Takeaway

• Pembrolizumab fails to improve survival in patients with platinum-pretreated recurrent and/or metastatic nasopharyngeal cancer vs chemotherapy.
• Incidence of treatment-related adverse events was lower with pembrolizumab.

Why this matters

• Findings do not support pembrolizumab monotherapy in this setting.
• Investigation of combination regimens involving programmed death-ligand 1 (PD-L1)/programmed cell death protein...